Iron deficiency (ID) is common in patients with cardiovascular disease. Up to 60% of patients
with coronary artery disease, and an even higher proportion of those with heart failure (HF) …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary hypertension (PH) is a feature of a variety of diseases and continues to harbor
high morbidity and mortality. The main consequence of PH is right-sided heart failure which …

Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Iron deficiency affects up to one-third of the world's population, and is particularly common in
elderly individuals and those with certain chronic diseases. Iron excess can be detrimental …

Numerous molecular abnormalities have been described in pulmonary arterial hypertension
(PAH), complicating the translation of candidate therapies to patients because, typically, 1 …